Skip to main content

Artialis appoints Benedikt Van Nieuwenhove as its new CEO

August 1st, 2023 Liège, Belgium – Artialis SA, a CRDO company offering preclinical, clinical and biotesting services, is pleased to announce Benedikt Van Nieuwenhove as its new Chief Executive Officer (CEO). Prof. Yves Henrotin, founder and former CEO of the company, will continue to serve as President and member of the board.

Benedikt Van Nieuwenhove is a seasoned executive with over 30 years of experience in the CRO field. Prof. Dr. Benedikt Van Nieuwenhove obtained his master’s degree in pharmaceutical sciences (1991) and his PhD (1997) from the University of Ghent. In 2000, he founded the “European Centre for Clinical Research Training” (ECCRT) and has been the Managing Director of ECCRT ever since. In 2007 he also became a member of the Board. From 2008-2011 he acted as the VP Global Operations of the Harrison Clinical Research group for which he became the CEO from 2011 to 2014, until the merger with Synteract. Since 2016, he has been lecturing “Management of Clinical Research” at the Faculty of Pharmaceutical Sciences, University of Ghent. In 2020, he got elected as President of the Belgian Association of CROs (BeCRO). Thanks to his insightful knowledge of the CRO world and having been in the field of Clinical Research for about three decades, Benedikt has been appointed as an independent board member of Artialis in 2020. Benedikt has a passion for lean management and loves to seek and create new business opportunities.

Yves Henrotin, President, commented: “We are delighted to announce that Benedikt has been appointed as our new CEO. We are convinced that Benedikt’s solid CRO knowledge and business development track record are great assets. Benedikt will be a great leader and CEO for Artialis and will help the company to excel in its next phase of growth. The board congratulates Benedikt and wishes him all the best in his new role. We are looking forward to working with Benedikt, who will lead Artialis to achieve its full potential on a global scale.”

Benedikt Van Nieuwenhove added: “I am passionate about the field in which Artialis is operating. I strongly believe in the value of its services, helping industries and academics to develop innovative products and to bring them faster to market. I am very excited to be given the opportunity to join Artialis in this CEO role. I thank the board for their trust, and I look forward to working with the whole team, whose vision and values I share.”

About Artialis SA

Founded in 2010 as a spin-off of the University of Liège (Belgium) by Prof.Yves Henrotin, Artialis is a Contract Research and Development Organization (CRDO) offering preclinical, clinical, and biotesting services. ARTIALIS’ mission is to provide high-quality studies and services that help companies to accelerate their product development.

Website: Artialis – Your partner for drug development

Contact for press and media

Benedikt Van Nieuwenhove:
Sandra Pietri :